Clinical Supply Risk Management: Find Your Single Points of Failure Before They Find You

Every clinical supply chain contains single points of failure. One manufacturing site for drug substance. One depot serving a whole region. One courier who really understands the lane into that difficult country. One person who knows how the IRT was actually configured. Most sponsors discover these facts the same way — during the disruption — and recent years supplied the full curriculum: a pandemic that grounded air freight, wars that closed routes, port congestion, energy shocks, and vendor bankruptcies. The lesson isn't that disruption is coming; it's that resilience is a design property. You either built it in, or you're improvising.

Where do clinical supply chains actually break?

Map the failure surface honestly and it clusters into five zones. Manufacturing: single-sourced drug substance or product, one fill-finish line, a sole supplier of a critical excipient or container — the deepest and slowest failures to recover. Network nodes: the depot whose license, warehouse, or workforce serves an entire region; the packaging site every kit flows through. Lanes: routes dependent on one carrier, one border crossing, one airport's cold-chain capability — the failures geopolitics keeps demonstrating. Vendors: financial failure, quality collapse, or capacity reallocation at any critical partner, including the IRT that everything transacts through. Knowledge: the individual — internal or vendor-side — whose departure would orphan a process. A useful audit question for each element: if this disappeared tomorrow, how long until a patient misses a dose? The answers, ranked, are your risk register.

How much resilience should a program buy?

Proportionate to consequence, not to anxiety. Resilience costs real money — dual sourcing, duplicate stocks, redundant lanes — and gold-plating everything is its own failure. The discipline is triage: score each risk on likelihood, impact, and time-to-recover, then spend where impact and recovery time are worst. A missed dose in a rare disease program with irreplaceable drug justifies redundancy that a well-stocked, multi-source Phase III program doesn't need. Time-to-recover deserves special respect: risks with month-long recoveries (a new import license, a re-qualified manufacturing site) demand pre-built alternatives, because no amount of crisis energy compresses a regulatory timeline.

What does practical mitigation look like?

A toolkit applied selectively:

• Split what's splittable. Inventory across two depots instead of one; shipments of critical batches divided across routes; stability samples stored separately from the stock they support.
• Pre-qualify the plan B. Backup couriers flown before they're needed, alternate lanes documented, a second labeling site qualified — the mitigation is worthless if its first use is also its first test.
• Buy strategic buffer, placed deliberately. Safety stock positioned upstream (central, generic, long-dated) covers many failures at once; the same buffer scattered downstream covers few. This is resilience buffer, sized and labeled as such — not the accidental overage stacking that masquerades as safety.
• Contract for continuity. Vendors' disaster-recovery obligations, capacity guarantees, and your step-in rights, agreed while everyone is friends.
• Document the tribal knowledge. Configurations, lane quirks, country contacts — written down, because resilience that lives in one head takes vacations.

What turns a plan into an actual capability?

Three habits. Monitoring: a light early-warning routine — vendor financial health, geopolitical watch on your lanes, weather seasons, regulatory changes — so disruptions arrive as forecasts, not surprises. Rehearsal: a yearly tabletop exercise ("our primary depot lost its license this morning — go") exposes more plan defects in two hours than two years of filing. Ownership: a named person who maintains the risk register, triggers the playbooks, and briefs leadership — because the board-level supply story should include resilience posture, and unowned plans decay into documents. When disruption does land, the response sequence is always the same: protect dosing continuity first, communicate early to sites and study teams, execute the pre-built alternative, and capture the lessons while they're expensive enough to remember.